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Yook Chin Chia1,2*, Hooi Min Lim1 and Siew Mooi Ching3,4Abstract
Background: Initiation of statin therapy as primary prevention particularly in those with mildly elevated cardiovascular
disease risk factors is still being debated. The 2013 ACC/AHA blood cholesterol guideline recommends initiation of
statin by estimating the 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the new pooled cohort risk
score. This paper examines the use of the pooled cohort risk score and compares it to actual use of statins in daily
clinical practice in a primary care setting.
Methods: We examined the use of statins in a randomly selected sample of patients in a primary care clinic. The
demographic data and cardiovascular risk parameters were captured from patient records in 1998. The pooled
cohort risk score was calculated based on the parameters in 1998. The use of statins in 1998 and 2007, a 10-year
interval, was recorded.
Results: A total of 847 patients were entered into the analysis. Mean age of the patients was 57.2 ± 8.4 years and
33.1% were male. The use of statins in 1998 was only 10.2% (n = 86) as compared to 67.5% (n = 572) in 2007. For
patients with LDL 70-189 mg/dl and estimated 10-year ASCVD risk ≥7.5% (n = 190), 60% (n = 114) of patients were
on statin therapy by 2007. There were 124 patients in whom statin therapy was not recommended according to
ACC/AHA guideline but were actually receiving statin therapy.
Conclusions: An extra 40% of patients need to be treated with statin if the 2013 ACC/AHA blood cholesterol
guideline is used. However the absolute number of patients who needed to be treated based on the ACC/AHA
guideline is lower than the number of patients actually receiving it in a daily clinical practice. The pooled cohort
risk score does not increase the absolute number of patients who are actually treated with statins. However these
findings and the use of the pooled cohort risk score need to be validated further.
Keywords: Pooled cohort, Risk score, AHA/ACC, Statin, Primary care, Atherosclerotic cardiovascular disease risk,
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Statins have been extensively studied both in primary
and secondary prevention of cardiovascular events [1-4].
Identifying those who need statin therapy is crucial as
we need to weigh the cardiovascular (CV) risk against
adverse events of drug therapy, so that under- or over-* Correspondence: chiayc@um.edu.my
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unless otherwise stated.treatment can be minimized. Therefore, cardiovascular
risk stratification tools have been developed to help
clinicians identify patients, particularly those with mildly
elevated cardiovascular risk factors, who should be
treated with statins [5].
Until recently, the NCEP ATP-III Framingham risk
score was used as a tool to stratify risk for the indication
of statin therapy [6]. In November 2013, the American
College of Cardiology and American Heart Association
(ACC/AHA) released a new guideline for the manage-
ment of blood cholesterol [7]. Patients with clinical
atherosclerotic cardiovascular disease (ASCVD) shouldd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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primary prevention, ACC/AHA guideline recommends
statin therapy for patients with LDL ≥190 mg/dl. Statin
therapy is also recommended for patients with diabetes
mellitus and LDL 70-189 mg/dl. Patients without diabetes
but with LDL 70-189 mg/dl and a 10-year ASCVD risk
≥7.5% based on the new pooled cohort risk score should be
given statin. The pooled cohort risk equation was derived
from pooled data of four large cohorts that included
both white and black men and women (Framingham
and the Framingham Offspring studies, Atherosclerosis
Risk in Communities, Cardiovascular Health Study and
Coronary Artery Risk Development in Young Adults).
Since the release of the 2013 ACC/AHA guideline
there has been a lot of debate and concern about the use
of this new pooled cohort risk score as it recommends a
much lower threshold of ≥7.5% for the initiation of
statins. Hence it is perceived to overestimate CV risk
and that more patients will need to be treated with statin
[8-10]. Currently, there are still very few studies explor-
ing the use of the pooled cohort risk score in different
populations. Hence, we examined the use of the pooled
cohort risk score that identifies patients who need statin
against patients who are actually receiving statin therapy
in a daily clinical practice in primary care.
Methods
Setting
This current study is part of a 10-year retrospective co-
hort study of randomly selected patients registered with
a primary care clinic. This clinic is an outpatient clinic
of University Malaya Medical Centre, a teaching hospital
in Kuala Lumpur, the capital city of Malaysia. This clinic
is run by 14 family medicine specialists, 30 vocational
trainees in family medicine and other medical officers.
This tertiary medical centre including its primary care
clinic serves a multi-ethnic population of 450,000 in the
surrounding area. The majority of our study the popula-
tion are middle class patients with around 11 years of
formal education. They are also representative of the
type of patients that are seen in primary care clinics in
Malaysia. Ethics approval was obtained from the Ethics
Committee of the University of Malaya Medical Centre.
Study population
This study is part of a retrospective cohort study for
validating the Framingham Risk Score in a primary
care Asian population. There were 970 patients in the
original cohort and 908 were in the age group 40–75
years (the age group in whom the pooled cohort risk
score is applicable according to the ACC/AHA guideline).
After excluding patients with incomplete data on LDL
level and statin use in 2007, 847 patients were eligible for
this analysis.Inclusion criteria
Adults aged 40–75 without clinical ASCVD who were
already registered in our centre in 1998 were eligible for
this study.
Exclusion criteria
Patients who did not have all the variables to calculate
the pooled cohort risk score at baseline were excluded.
Those patients with incomplete data on LDL level and
statin use in 2007 were excluded as well.
Data collection
Random numbers were generated by computer based on
the patients’ registration number with the clinic. Baseline
data was collected in 1998 and follow-up data collected
in 2007, a 10-year interval. We extracted the patients’
information from their paper-based records manually.
Socio-demographic data and co-morbidities were re-
corded. Blood pressure was measured by the attending
doctor using mercury sphygmomanometer as part of
daily routine care. Diagnosis of hypertension in our
clinic is made in accordance with standard recommenda-
tions i.e. blood pressure ≥140/90 mmHg based on at least
2 blood pressure measurements at least 2 weeks apart
[11]. Anti-hypertensive drug use was also recorded.
Diabetes mellitus was defined as documented by the
attending physician or the use of hypoglycaemic agents
or both. HbA1c levels of diabetic patients were also
captured. Smokers were defined if they were still smoking
currently. Non-smokers were those who never smoked
or currently not smoking regardless of when they had
stopped smoking. Renal function was determined by the
estimated glomerular filtration rate (eGFR) based on the
Cockcroft-Gault formula [12].
Total cholesterol, LDL and HDL cholesterol levels
were captured. Statin use in 1998 and 2007 were
recorded. We calculated the pooled cohort risk score
for those without diabetes but with LDL 70-189 mg/dl
using the online pooled cohort risk calculator provided
by American Heart Association [13]. ASCVD events
from 1998 until 2007 (10-year period) were collected.
ASCVD events were defined as nonfatal myocardial
infarction (MI), coronary heart disease (CHD) death,
nonfatal and fatal stroke in accordance to the ACC/
AHA guideline.
Statistical analysis
All statistical analysis was done using the Statistical
Package for Social Sciences (SPSS version 16). Categor-
ical data are reported as proportions (percentage). Mean
was used for continuous variables that were normally
distributed. Median and interquartile range were used
for variables that were not normally distributed.
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847 patients who fulfilled the inclusion criteria were re-
cruited into our analysis. Overall, the baseline mean age of
the patients was 57.2 years with 33.1% male. Table 1 shows
the cardiovascular risk profile in 1998 and 2007. Only 184
(8%) of patients had chronic kidney disease stage 3 and
above in 1998. 86 (10.2%) of patients were on statin ther-
apy in 1998 compared to 572 (67.5%) in 2007.
Figure 1 shows the comparison of the ACC/AHA
guideline to the use of statins in actual primary care
practice. As patients with clinical ASCVD in 1998 were
excluded, the first major recommendation group is patients
with LDL ≥ 190 mg/dl (n = 153). 90.8% (n = 139) of our
patients of this group were on a statin by the end of the
10-year period. For patients with diabetes mellitus and
LDL 70-189 mg/dl, only 63.9% (n = 195) of diabetic pa-
tients were on statin.Table 1 Cardiovascular disease risk profile for adults age of 4
All adults (N = 847)
Mean age - yr
Age <65 (n, %)
Age ≥65 (n, %)







Low-density lipoprotein ≥190 mg/dl (n, %)
Cholesterol
Median total – mg/dl (IQR)
Median low-density lipoprotein – mg/dl (IQR)
Median high-density lipoprotein – mg/dl (IQR)
Mean systolic blood pressure - mmHg
Mean diastolic blood pressure - mmHg
Patients on antihypertensive agent (n, %)
Diabetes mellitus (n, %)
Mean HbA1c - %
Current smoking (n, %)
Mean creatinine – umol/L




Use of statins (n, %)
IQR Interquartile range.For patients without diabetes but with LDL 70-
189 mg/dl, we estimated their 10-year ASCVD risk
using the pooled cohort risk score to determine the
indication for statin therapy. There were 190 patients
with estimated 10-year ASCVD ≥7.5%. Only 60.0%
(n = 114) of these patients were receiving statin. Hence,
an extra 40% (n = 76) of patients with risk score ≥7.5%
need to be treated with statins if the recommendations
of the ACC/AHA guidelines were used. On the other
hand, 62.3% (n = 124) of patients were receiving statin
when it was not indicated based on 10-year ASCVD
risk score.
A total of 35 (4.1%) ASCVD events occurred over the
10 year period (31 non-fatal strokes, 1 fatal stroke and 3
non-fatal CHD) (Figure 1). 6.6% of diabetic patients with
LDL 70-189 mg/dl had ASCVD events. For those pa-
tients with LDL 70-189 mg/dl and estimated 10-year0 and 75 years in 1998 and their profile in 2007
Year 1998 Year 2007
57.2 ± 8.4 67.1 ± 8.4
672 (79.3) 340 (40.1)
175 (20.7) 507 (59.9)
280 (33.1) 280 (33.1)
191 (22.6) 191 (22.6)
389 (45.9) 389 (45.9)
256 (30.2) 256 (30.2)
11 (1.3) 11 (1.3)
26.5 ± 4.64 26.1 ± 4.7
153 (11.5) 14 (1.7)
232.0 (208.8-259.1) 189.5 (166.3-216.6)
158.2 (133.2-181.0) 113.3 (92.0-136.2)
46.4 (38.7-54.1) 48.0 (40.8-56.8)
140.4 ± 18.3 135.0 ± 16.6
84.65 ± 10.1 78.8 ± 8.2
503 (59.4) 735 (86.6)
379 (44.7) 508 (60.0)
7.73 ± 1.8 7.66 ± 1.6
61 (6.0) 61 (6.0)
79.8 ± 23.7 85.2 ± 40.8
78.1 ± 26.2 (n = 779) 67.8 ± 27.0 (n = 663)
5 (0.6) 32 (3.8)
179 (21.1) 254 (30.0)
595 (92.0) 377 (44.5)
86 (10.2) 576 (67.5)
Figure 1 Comparison of use of the 2013 ACC/AHA blood cholesterol guideline to actual use of statin in a primary care setting and
ASCVD events.
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10 years. The pooled cohort risk score overestimated the
ASCVD risk in our study population. For those patients
in whom statin therapy was not recommended (n = 199),
5 ASCVD events occurred (2.5%).
Discussion
Clinicians frequently face a dilemma when deciding on
statin initiation as primary prevention, particularly in
those without diabetes and those with apparently mildly
elevated cardiovascular disease risk factors when the
indication is less clear and evidence less strong. The
recent ACC/AHA guideline suggests patients should be
treated with statins if their pooled cohort risk score is
≥7.5%. This lower threshold for initiating statin treat-
ment in contrast to the higher threshold used previously
would suggest that many more patients will need to
receive statins and that overtreatment will occur. This is
of concern particularly as a recent report suggests that
subjects with lower risk actually derive no benefit but
have more harm from treatment with statins [14]. How-
ever the recently updated NICE guidelines also supports
initiating statin therapy at lower CV risk i.e. ≥10% albeit
using the new QRISK2 score and not the AHA/ACCpooled cohort scoring system. The NICE recommenda-
tion has also been supported by others [15,16].
Based on our study, an extra 40% of patients (n = 76)
will need to be treated if the pooled cohort risk score
was used. This is consistent with a study on use of the
2013 ACC/AHA guideline in the American population
based on National Health and Nutrition Examination
Survey (NHANES III) where an extra 15.9% of patients,
equivalent to 12.8 million more people will need to be
treated with statins when compared with the ATP III
guidelines [8]. Another study also using the ACC/AHA
guideline in a non-American population in Netherlands
showed that more adults will also need statin therapy
whereby nearly all men and two thirds of women will
need to be treated [9].
However in our cohort of patients, we found that
more than half of patients (62.3%, n = 124) were actu-
ally receiving statin when statin therapy would not have
been indicated based on the new pooled cohort risk
score recommendations at baseline. However their statin
therapy may have been started because they developed
diabetes, hypertension or dyslipidaemia which would
have increased their CV risk, sometime in the 10 years
of follow-up.
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sarily” with statins in actual clinical practice (n = 124) is
even higher than the extra number of patients who need
to be treated based on recommendations of the new
AHA/ACC guideline (n = 76). On balance, the total
number of patients recommended by the ACC/AHA
guidelines did not exceed the number of patients who
were actually receiving statin in real-life daily clinical
practice in primary care where most of the lower to
moderate risk patients are seen. Perhaps the pooled
cohort risk score can guide clinicians in identifying the
correct patients for statin therapy, thus avoiding over-
or under-treatment. Johansen et al. also pointed out that
the pooled cohort risk score may guide the clinicians to
focus on patients’ CV risk when initiating statin therapy
instead of the lipid profile alone and hence avoid under-
treatment in high risk people [17].
According to the NCEP ATP III guidelines, diabetes
mellitus is considered a cardiovascular heart disease
(CHD) risk equivalent [18]. Clearly this group of
patients has high cardiovascular risk and statin therapy
will be of benefit to them [19-21]. Our study has also
shown that not all patients with diabetes mellitus were
receiving statin therapy and this is consistent with
findings in other studies [17,22]. Greater effort will be
needed to get all patients with diabetes to be on statin
therapy.
The pooled cohort risk score is meant to be used to
stratify risk for initiation of statin therapy. Although our
patients were not risk scored in 1998 for statin use, 60%
of them deemed to need statin were eventually receiving
some time over the 10 year period. This implies that the
use of the risk score identifies patients earlier to receive
statins and therefore could be helpful to clinicians in
deciding when to start statin.
Strengths and limitations
A strength of our study is that it is done in a primary
care clinic where most patients who are at lower risk
for CVD are seen. These are the very same patients in
whom initiation of statin therapy as primary preven-
tion is less clear and is when a global CVD risk is most
helpful to stratify risk for statin therapy. Furthermore
the period studied is relatively long and allows tracking
of the use of statin over 10 years. Our study also
reflects true clinical practice of the use of statin in
primary care. There are several limitations in our
study. Firstly, patients with incomplete data, especially
HDL cholesterol level which is an important factor in
the pooled cohort risk equation, were excluded in this
analysis. We also do not have data on when statin was
initiated. However patients who needed statins did
eventually receive statins some time in the 10-year
period.Conclusions
An extra 40% of patients need to be treated with statin if
2013 ACC/AHA blood cholesterol guideline is used.
However the absolute number of patients needed to be
treated based on the ACC/AHA guideline is lower than
the actual number of patients who were receiving it in
daily clinical practice. The pooled cohort risk score may
serve as an appropriate tool to guide clinicians on the
initiation of statin therapy. However, further studies are
needed to validate the pooled cohort risk equation.
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